Early detection biomarkers for ovarian cancer

Journal of Oncology

Volumn , Issue , 2012, Pages

  Sarojini, Sreeja ^a   Tamir, Ayala ^a   Lim, Heejin ^a   Li, Shihong ^b   Zhang, Shifang ^b   Goy, Andre ^a   Pecora, Andrew ^a   Suh, K Stephen ^a  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b GENEWIZ INC   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; DNA; FOLATE RECEPTOR 1; GLUTATHIONE TRANSFERASE; HUMAN EPIDIDYMIS PROTEIN 4; KALLIKREIN; MESOTHELIN; MICRORNA; OSTEOPONTIN; PROSTASIN; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CANCER SCREENING; CARCINOGENESIS; CLINICAL TRIAL; EARLY DIAGNOSIS; HUMAN; OVARY CANCER; REVIEW; TRANSVAGINAL ECHOGRAPHY;

EID: 84872790574     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/709049     Document Type: Review

References (150)

1. American Cancer Society, Cancer Facts & Figures 2012 2012 Atlanta, Ga, USA American Cancer Society
2. Chu C. S., Rubin S. C., Screening for ovarian cancer in the general population. Best Practice and Research Clinical Obstetrics and Gynaecology 2006 20 2 307 320 (Pubitemid 43380602)
3. Badgwell D., Bast R. C. Jr., Early detection of ovarian cancer. Disease Markers 2007 23 5-6 397 410 2-s2.0-36448975871 (Pubitemid 350171267)
4. Jacobs I. J., Menon U., Progress and challenges in screening for early detection of ovarian cancer. Molecular and Cellular Proteomics 2004 3 4 355 366 2-s2.0-2542609900 10.1074/mcp.R400006-MCP200 (Pubitemid 38702089)
5. Cho K. R., Shih L. M., Ovarian cancer. Annual Review of Pathology 2009 4 287 313 10.1146/annurev.pathol.4.110807.092246
6. Antoniou A., Pharoah P. D. P., Narod S., Risch H. A., Eyfjord J. E., Hopper J. L., Loman N., Olsson H., Johannsson O., Borg Å., Pasini B., Radice P., Manoukian S., Eccles D. M., Tang N., Olah E., Anton-Culver H., Warner E., Lubinski J., Gronwald J., Gorski B., Tulinius H., Thorlacius S., Eerola H., Nevanlinna H., Syrjäkoski K., Kallioniemi O.-P., Thompson D., Evans C., Peto J., Lalloo F., Evans D. G., Easton D. F., Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. American Journal of Human Genetics 2003 72 5 1117 1130 10.1086/375033 (Pubitemid 36530000)
7. Antoniou A. C., Cunningham A. P., Peto J., Evans D. G., Lalloo F., Narod S. A., Risch H. A., Eyfjord J. E., Hopper J. L., Southey M. C., Olsson H., Johannsson O., Borg A., Passini B., Radice P., Manoukian S., Eccles D. M., Tang N., Olah E., Anton-Culver H., Warner E., Lubinski J., Gronwald J., Gorski B., Tryggvadottir L., Syrjakoski K., Kallioniemi O. P., Eerola H., Nevanlinna H., Pharoah P. D. P., Easton D. F., The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. British Journal of Cancer 2008 98 8 1457 1466 2-s2.0-42149193041 10.1038/sj.bjc.6604305 (Pubitemid 351543573)
8. Chen S., Iversen E. S., Friebel T., Finkelstein D., Weber B. L., Eisen A., Peterson L. E., Schildkraut J. M., Isaacs C., Peshkin B. N., Corio C., Leondaridis L., Tomlinson G., Dutson D., Kerber R., Amos C. I., Strong L. C., Berry D. A., Euhus D. M., Parmigiani G., Characterization of BRCA1 and BRCA2 mutations in a large United States sample. Journal of Clinical Oncology 2006 24 6 863 871 2-s2.0-33644895048 10.1200/JCO.2005.03.6772 (Pubitemid 46638837)
9. Gayther S. A., Warren W., Mazoyer S., Russell P. A., Harrington P. A., Chiano M., Seal S., Hamoudi R., van Rensburg E. J., Dunning A. M., Love R., Evans G., Easton D., Clayton D., Stratton M. R., Ponder B. A. J., Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nature Genetics 1995 11 4 428 433 2-s2.0-0028844202
10. Struewing J. P., Hartge P., Wacholder S., Baker S. M., Berlin M., McAdams M., Timmerman M. M., Brody L. C., Tucker M. A., The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. The New England Journal of Medicine 1997 336 20 1401 1408 2-s2.0-0030910022 10.1056/NEJM199705153362001 (Pubitemid 27208598)
11. Bast R. C. Jr., Biomarkers for ovarian cancer: new technologies and targets to address persistently unmet needs. Cancer Biomarkers 2010 8 4-5 161 166 10.3233/CBM-2011-0209
12. Suh K. S., Park S. W., Castro A., Patel H., Blake P., Liang M., Goy A., Ovarian cancer biomarkers for molecular biosensors and translational medicine. Expert Review of Molecular Diagnostics 2010 10 8 1069 1083 2-s2.0-78649265888 10.1586/erm.10.87
13. Høgdall E., Cancer antigen 125 and prognosis. Current Opinion in Obstetrics and Gynecology 2008 20 1 4 8 10.1097/GCO.0b013e3282f2b124
14. Bast R. C. Jr., Klug T. L., John E. S., A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. The New England Journal of Medicine 1983 309 15 883 887 2-s2.0-0020559574 (Pubitemid 13014028)
15. Bast R. C. Jr., Badgwell D., Lu Z., Marquez R., Rosen D., Liu J., Baggerly K. A., Atkinson E. N., Skates S., Zhang Z., Lokshin A., Menon U., Jacobs I., Lu K., New tumor markers: CA125 and beyond. International Journal of Gynecological Cancer 2005 15 6, supplement 3 274 281 (Pubitemid 43096594)
16. Duffy M. J., Bonfrer J. M., Kulpa J., Rustin G. J. S., Soletormos G., Torre G. C., Tuxen M. K., Zwirner M., CA125 in ovarian cancer: European group on tumor markers guidelines for clinical use. International Journal of Gynecological Cancer 2005 15 5 679 691 2-s2.0-28944450024 10.1111/j.1525-1438. 2005.00130.x (Pubitemid 41783071)
17. Čolaković S., Lukiç V., Mitroviç L., Jeliç S., Šušnjar S., Marinkoviç J., Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer. International Journal of Biological Markers 2000 15 2 147 152 (Pubitemid 30389362)
18. Rein B. J. D., Gupta S., Dada R., Agarwal A., Safi J., Michener C., Potential markers for detection and monitoring of ovarian cancer. Journal of Oncology 2011 2011 17 2-s2.0-79959199177 10.1155/2011/475983 475983
19. McIntosh M. W., Drescher C., Karlan B., Scholler N., Urban N., Hellstrom K. E., Hellstrom I., Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecologic Oncology 2004 95 1 9 15 2-s2.0-4644237492 10.1016/j.ygyno.2004.07.039 (Pubitemid 39286271)
20. Bast R.C. Jr., Xu F.-J., Yu Y.-H., Barnhill S., Zhang Z., Mills G. B., CA 125: the past and the future. International Journal of Biological Markers 1998 13 4 179 187 (Pubitemid 29178546)
21. Guppy A. E., Rustin G. J. S., CA125 response: can it replace the traditional response criteria in ovarian cancer? Oncologist 2002 7 5 437 443 2-s2.0-0036409129 10.1634/theoncologist.7-5-437 (Pubitemid 35266136)
22. Tcherkassova J., Abramovich C., Moro R., Chen C., Schmit R., Gerber A., Moro R., Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer. Tumor Biology 2011 32 4 831 838 2-s2.0-79957453281 10.1007/s13277-011-0186-1
23. Moore R. G., McMeekin D. S., Brown A. K., DiSilvestro P., Miller M. C., Allard W. J., Gajewski W., Kurman R., Bast R. C., Skates S. J., A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecologic Oncology 2009 112 1 40 46 2-s2.0-57649088474 10.1016/j.ygyno.2008.08.031
24. Jacobs I., Gentry-Maharaj A., Burnell M., Manchanda R., Singh N., Sharma A., Ryan A., Seif M. W., Amso N. N., Turner G., Brunell C., Fletcher G., Rangar R., Ford K., Godfrey K., Lopes A., Oram D., Herod J., Williamson K., Scott I., Jenkins H., Mould T., Woolas R., Murdoch J., Dobbs S., Leeson S., Cruickshank D., Skates S. J., Fallowfield L., Parmar M., Campbell S., Menon U., Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. The Lancet Oncology 2011 12 1 38 48 2-s2.0-78650687714 10.1016/S1470-2045(10)70268-0
25. Menon U., Gentry-Maharaj A., Hallett R., Ryan A., Burnell M., Sharma A., Lewis S., Davies S., Philpott S., Lopes A., Godfrey K., Oram D., Herod J., Williamson K., Seif M. W., Scott I., Mould T., Woolas R., Murdoch J., Dobbs S., Amso N. N., Leeson S., Cruickshank D., Mcguire A., Campbell S., Fallowfield L., Singh N., Dawnay A., Skates S. J., Parmar M., Jacobs I., Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK collaborative trial of ovarian cancer screening (UKCTOCS). The Lancet Oncology 2009 10 4 327 340 2-s2.0-63149087256 10.1016/S1470-2045(09)70026-9
26. Comamala M., Pinard M., Thériault C., Matte I., Albert A., Boivin M., Beaudin J., Piché A., Rancourt C., Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells. British Journal of Cancer 2011 104 6 989 999 2-s2.0-79952704437 10.1038/bjc.2011.34
27. Thériault C., Pinard M., Comamala M., Migneault M., Beaudin J., Matte I., Boivin M., Piché A., Rancourt C., MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. Gynecologic Oncology 2011 121 3 434 443 2-s2.0-79957525887 10.1016/j.ygyno.2011.02.020
28. Dorigo O., Berek J. S., Personalizing CA125 levels for ovarian cancer screening. Cancer Prevention Research 2011 4 9 1356 1359 10.1158/1940-6207.CAPR- 11-0378
29. Skates S. J., Mai P., Horick N. K., Piedmonte M., Drescher C. W., Isaacs C., Armstrong D. K., Buys S. S., Rodriguez G. C., Horowitz I. R., Berchuck A., Daly M. B., Domchek S., Cohn D. E., van Le L., Schorge J. O., Newland W., Davidson S. A., Barnes M., Brewster W., Azodi M., Nerenstone S., Kauff N. D., Fabian C. J., Sluss P. M., Nayfield S. G., Kasten C. H., Finkelstein D. M., Greene M. H., Lu K., Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prevention Research 2011 4 9 1401 1408 10.1158/1940-6207.CAPR-10-0402
30. Jacobs I. J., Skates S., Davies A. P., Woolas R. P., Jeyerajah A., Weidemann P., Sibley K., Oram D. H., Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. British Medical Journal 1996 313 7069 1355 1358 2-s2.0-0029796210 (Pubitemid 26400120)
31. Muller C. Y., Doctor, should I get this new ovarian cancer test-OVA1? Obstetrics and Gynecology 2010 116 2 246 247 2-s2.0-77955130122 10.1097/AOG.0b013e3181e934ba
32. Ueland F. R., Desimone C. P., Seamon L. G., Miller R. A., Goodrich S., Podzielinski I., Sokoll L., Smith A., van Nagell J. R., Zhang Z., Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstetrics and Gynecology 2011 117 6 1289 1297 2-s2.0-79958152284 10.1097/AOG.0b013e31821b5118
33. Hellstrom I., Hellstrom K. E., SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Advances in Experimental Medicine and Biology 2008 622 15 21 2-s2.0-47049093283 10.1007/978-0-387-68969-2-2
34. Heliström I., Raycraft J., Hayden-Ledbetter M., Ledbetter J. A., Schummer M., McIntosh M., Drescher C., Urban N., Hellström K. E., The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Research 2003 63 13 3695 3700 2-s2.0-0038756386 (Pubitemid 36793054)
35. Montagnana M., Danese E., Giudici S., Franchi M., Guidi G. C., Plebani M., Lippi G., HE4 in ovarian cancer: from discovery to clinical application. Advances in Clinical Chemistry 2011 55 1 20 10.1016/B978-0-12-387042-1.00001-0
36. Moore R. G., Miller M. C., Disilvestro P., Landrum L. M., Gajewski W., Ball J. J., Skates S. J., Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstetrics and Gynecology 2011 118 2 280 288 2-s2.0-79961056124 10.1097/AOG.0b013e318224fce2
37. Chang X., Ye X., Dong L., Cheng H., Cheng Y., Zhu L., Liao Q., Zhao Y., Tian L., Fu T., Chen J., Cui H., Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma. International Journal of Gynecological Cancer 2011 21 5 852 858 10.1097/IGC.0b013e31821a3726
38. Li J., Dowdy S., Tipton T., Podratz K., Lu W. G., Xie X., Jiang S. W., HE4 as a biomarker for ovarian and endometrial cancer management. Expert Review of Molecular Diagnostics 2009 9 6 555 566 2-s2.0-69949188760 10.1586/erm.09.39
39. Molina R., Escudero J. M., Augé J. M., Filella X., Foj L., Torné A., Lejarcegui J., Pahisa J., HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biology 2011 32 6 1087 1095
40. Moore R. G., Brown A. K., Miller M. C., Skates S., Allard W. J., Verch T., Steinhoff M., Messerlian G., DiSilvestro P., Granai C. O., Bast R. C. Jr., The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecologic Oncology 2008 108 2 402 408 10.1016/j.ygyno.2007.10.017 (Pubitemid 351174295)
41. Escudero J. M., Auge J. M., Filella X., Torne A., Pahisa J., Molina R., Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clinical Chemistry 2011 57 11 1534 1544 10.1373/clinchem.2010.157073
42. Yurkovetsky Z., Skates S., Lomakin A., Nolen B., Pulsipher T., Modugno F., Marks J., Godwin A., Gorelik E., Jacobs I., Menon U., Lu K., Badgwell D., Bast R. C., Lokshin A. E., Development of a multimarker assay for early detection of ovarian cancer. Journal of Clinical Oncology 2010 28 13 2159 2166 2-s2.0-77952315345 10.1200/JCO.2008.19.2484
43. Lu R., Sun X., Xiao R., Zhou L., Gao X., Guo L., Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility. Biochemical and Biophysical Research Communications 2012 419 2 274 280 10.1016/j.bbrc.2012.02.008
44. Li A. J., New biomarkers for ovarian cancer: OVA1 and ROMA in diagnosis selective use of these new tests may lead to better outcomes for women with adnexal masses or epithelial ovarian cancer. Contemporary Ob/Gyn 2012 57 4
45. Li F., Tie R., Chang K., Wang F., Deng S., Lu W., Yu L., Chen M., Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and ca125 in predicting epithelial ovarian cancer: a meta-analysis. BMC Cancer 2012 12, article 258 10.1186/1471-2407-12-258
46. Karlsen M. A., Sandhu N., Høgdall C., Christensen I. J., Nedergaard L., Lundvall L., Engelholm S. A., Pedersen A. T., Hartwell D., Lydolph M., Laursen I. A., Høgdall E. V. S., Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecologic Oncology 2012 127 2 379 383 10.1016/j.ygyno.2012.07.106
47. Hassan R., Kreitman R. J., Pastan I., Willingham M. C., Localization of mesothelin in epithelial ovarian cancer. Applied Immunohistochemistry and Molecular Morphology 2005 13 3 243 247 2-s2.0-23844542990 10.1097/01.pai. 00000141545.36485.d6 (Pubitemid 41209017)
48. Hassan R., Ho M., Mesothelin targeted cancer immunotherapy. European Journal of Cancer 2008 44 1 46 53 2-s2.0-37249038187 10.1016/j.ejca.2007.08.028 (Pubitemid 350262830)
49. Scholler N., Garvik B., Hayden-Ledbetter M., Kline T., Urban N., Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery. Cancer Letters 2007 247 1-2 130 136 2-s2.0-33845672642 10.1016/j.canlet.2006.03.029 (Pubitemid 44959415)
50. Rump A., Morikawa Y., Tanaka M., Minami S., Umesaki N., Takeuchi M., Miyajima A., Binding of ovarian cancer antigen CA125/MUC61 to mesothelin mediates cell adhesion. The Journal of Biological Chemistry 2004 279 10 9190 9198 2-s2.0-1542365125 10.1074/jbc.M312372200 (Pubitemid 38295982)
51. Lowe K. A., Shah C., Wallace E., Anderson G., Paley P., McIntosh M., Andersen M. R., Scholler N., Bergan L., Thorpe J., Urban N., Drescher C. W., Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiology Biomarkers and Prevention 2008 17 9 2480 2487 2-s2.0-53349160350 10.1158/1055-9965.EPI-08-0150
52. Huang C. Y., Cheng W. F., Lee C. N., Su Y. N., Chien S. C., Tzeng Y. L., Hsieh C. Y., Chen C. A., Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor. Anticancer Research 2006 26 6 4721 4728 2-s2.0-33846018044
53. Badgwell D., Lu Z., Cole L., Fritsche H., Atkinson E. N., Somers E., Allard J., Moore R. G., Lu K. H., Bast R. C., Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecologic Oncology 2007 106 3 490 497 2-s2.0-34548133375 10.1016/j.ygyno.2007.04.022 (Pubitemid 47302455)
54. Chang M. C., Chen C. A., Chen P. J., Chiang Y. C., Chen Y. L., Mao T. L., Lin H. W., Chiang W. H. L., Cheng W. F., Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways. Biochemical Journal 2012 442 2 293 302 10.1042/BJ20110282
55. Diamandis E. P., Scorilas A., Fracchioli S., van Gramberen M., de Bruijn H., Henrik A., Soosaipillai A., Grass L., Yousef G. M., Stenman U. H., Massobrio M., van der Zee A. G. J., Vergote I., Katsaros D., Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. Journal of Clinical Oncology 2003 21 6 1035 1043 2-s2.0-0037445253 10.1200/JCO.2003.02.022 (Pubitemid 46594132)
56. Yousef G. M., Diamandis E. P., Expanded human tissue kallikrein family-a novel panel of cancer biomarkers. Tumor Biology 2002 23 3 185 192 2-s2.0-0036562226 10.1159/000064027 (Pubitemid 44858310)
57. Yousef G. M., Diamandis E. P., The new human tissue kallikrein gene family: structure, function, and association to disease. Endocrine Reviews 2001 22 2 184 204 2-s2.0-0035018273 10.1210/er.22.2.184 (Pubitemid 32458158)
58. Borgoño C. A., Michael I. P., Diamandis E. P., Human tissue kallikreins: physiologic roles and applications in cancer. Molecular Cancer Research 2004 2 5 257 280 2-s2.0-3543150203 (Pubitemid 39031076)
59. Pavlopoulou A., Pampalakis G., Michalopoulos I., Sotiropoulou G., Evolutionary history of tissue kallikreins. PLoS ONE 2010 5 11 2-s2.0-78249243096 10.1371/journal.pone.0013781 e13781
60. Stone O. A., Richer C., Emanueli C., van Weel V., Quax P. H. A., Katare R., Kraenkel N., Campagnolo P., Barcelos L. S., Siragusa M., Sala-Newby G. B., Baldessari D., Mione M., Vincent M. P., Benest A. V., Al Haj Zen A., Gonzalez J., Bates D. O., Alhenc-Gelas F., Madeddu P., Critical role of tissue kallikrein in vessel formation and maturation: implications for therapeutic revascularization. Arteriosclerosis, Thrombosis, and Vascular Biology 2009 29 5 657 664 10.1161/ATVBAHA.108.182139
61. Dominek P., Campagnolo P., Zadeh M. H., Kränkel N., Chilosi M., Sharman J. A., Caporali A., Mangialardi G., Spinetti G., Emanueli C., Pignatelli M., Madeddu P., Role of human tissue kallikrein in gastrointestinal stromal tumour invasion. British Journal of Cancer 2010 103 9 1422 1431 2-s2.0-78049285304 10.1038/sj.bjc.6605906
62. Borgoño C. A., Diamandis E. P., The emerging roles of human tissue kallikreins in cancer. Nature Reviews Cancer 2004 4 11 876 890 2-s2.0-8144222388 10.1038/nrc1474 (Pubitemid 39472954)
63. Oikonomopoulou K., Hansen K. K., Saifeddine M., Vergnolle N., Tea I., Diamandis E. P., Hollenberg M. D., Proteinase-mediated cell signalling: targeting proteinase-activated receptors (PARs) by kallikreins and more. Biological Chemistry 2006 387 6 677 685 2-s2.0-33745673593 10.1515/BC.2006.086 (Pubitemid 43964789)
64. Dong Y., Kaushal A., Bui L., Chu S., Fuller P. J., Nicklin J., Samaratunga H., Clements J. A., Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. Clinical Cancer Research 2001 7 8 2363 2371 2-s2.0-0034890325 (Pubitemid 32751637)
65. Obiezu C. V., Shan S. J. C., Soosaipillai A., Luo L. Y., Grass L., Sotiropoulou G., Petraki C. D., Papanastasiou P. A., Levesque M. A., Diamandis E. P., Human kallikrein 4: quantitative study in tissues and evidence for its secretion into biological fluids. Clinical Chemistry 2005 51 8 1432 1442 2-s2.0-23044450255 10.1373/clinchem.2005.049692 (Pubitemid 41060875)
66. Obiezu C. V., Scorilas A., Katsaros D., Massobrio M., Yousef G. M., Fracchioli S., Rigault de la Longrais I. A., Arisio R., Diamandis E. P., Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. Clinical Cancer Research 2001 7 8 2380 2386 2-s2.0-0034881126 (Pubitemid 32751639)
67. Obiezu C. V., Diamandis E. P., Human tissue kallikrein gene family: applications in cancer. Cancer Letters 2005 224 1 1 22 2-s2.0-19344371357 10.1016/j.canlet.2004.09.024 (Pubitemid 40720363)
68. Dong Y., Kaushal A., Brattsand M., Nicklin J., Clements J. A., Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers. Clinical Cancer Research 2003 9 5 1710 1720 2-s2.0-0038327753 (Pubitemid 36554595)
69. Shan S. J. C., Scorilas A., Katsaros D., Diamandis E. P., Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects. British Journal of Cancer 2007 96 2 362 372 2-s2.0-33846473583 10.1038/sj.bjc.6603556 (Pubitemid 46160644)
70. Emami N., Diamandis E. P., Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. Clinical Chemistry 2008 54 10 1600 1607 2-s2.0-54049150854 10.1373/clinchem.2008.105189
71. Diamandis E. P., Yousef G. M., Soosaipillai A. R., Grass L., Porter A., Little S., Sotiropoulou G., Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. Clinical Biochemistry 2000 33 5 369 375 2-s2.0-0033778286 10.1016/S0009-9120(00)00145-4
72. Ashby E. L., Kehoe P. G., Love S., Kallikrein-related peptidase 6 in Alzheimer's disease and vascular dementia. Brain Research 2010 1363 1 10 2-s2.0-78149468228 10.1016/j.brainres.2010.09.017
73. Jacobs I. J., Skates S. J., MacDonald N., Menon U., Rosenthal A. N., Davies A. P., Woolas R., Jeyarajah A. R., Sibley K., Lowe D. G., Oram D. H., Screening for ovarian cancer: a pilot randomised controlled trial. The Lancet 1999 353 9160 1207 1210 2-s2.0-0033541548 10.1016/S0140-6736(98)10261-1 (Pubitemid 29168457)
74. Kuzmanov U., Jiang N., Smith C. R., Soosaipillai A., Diamandis E. P., Differential N-glycosylation of kallikrein 6 derived from ovarian cancer cells or the central nervous system. Molecular and Cellular Proteomics 2009 8 4 791 798 2-s2.0-66149104552 10.1074/mcp.M800516-MCP200
75. Henkhaus R. S., Roy U. K. B., Cavallo-Medved D., Sloane B. F., Gerner E. W., Ignatenko N. A., Caveolin-1 mediated expression and secretion of Kallikrein 6 in colon cancer cells. Neoplasia 2008 10 2 140 148 2-s2.0-39049089569 10.1593/neo.07817 (Pubitemid 351240880)
76. Talieri M., Diamandis E. P., Gourgiotis D., Mathioudaki K., Scorilas A., Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma. Thrombosis and Haemostasis 2004 91 1 180 186 2-s2.0-1642515074 (Pubitemid 38111235)
77. Kyriakopoulou L. G., Yousef G. M., Scorilas A., Katsaros D., Massobrio M., Fracchioli S., Diamandis E. P., Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. Clinical Biochemistry 2003 36 2 135 143 2-s2.0-0037336894 10.1016/S0009-9120(02)00446-0 (Pubitemid 36287493)
78. Tanimoto H., Underwood L. J., Shigemasa K., Yan Y., Clarke J., Parmley T. H., O'Brien T. J., The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells. Cancer 1999 86 10 2074 2082 10.1002/(SICI)1097-0142(19991115)86: 10<2074::AID-CNCR27>3.0.CO;2-3
79. Kishi T., Grass L., Soosaipillai A., Shimizu-Okabe C., Diamandis E. P., Human kallikrein 8: immunoassay development and identification in tissue extracts and biological fluids. Clinical Chemistry 2003 49 1 87 96 2-s2.0-0037230511 10.1373/49.1.87 (Pubitemid 36078557)
80. Shih L. M., Salani R., Fiegl M., Wang T. L., Soosaipillai A., Marth C., Müller-Holzner E., Gastl G., Zhang Z., Diamandis E. P., Ovarian cancer specific kallikrein profile in effusions. Gynecologic Oncology 2007 105 2 501 507 2-s2.0-34247141934 10.1016/j.ygyno.2007.01.018 (Pubitemid 46590345)
81. Koh S. C. L., Razvi K., Chan Y. H., Narasimhan K., Ilancheran A., Low J. J., Choolani M., Sahil F., Lutan D., Siddik D., Suwiyoga K., Budiana G., Pradjitmo H., Saleh A. Z., Aziz M. F., Winarto H., Thanh P. V., Hoan N. K. H., Ravichandran I., Dominic N., The association with age, human tissue kallikreins 6 and 10 and hemostatic markers for survival outcome from epithelial ovarian cancer. Archives of Gynecology and Obstetrics 2011 284 1 183 190 2-s2.0-79958793918 10.1007/s00404-010-1605-z
82. Pépin D., Shao Z. Q., Huppé G., Wakefield A., Chu C. W., Sharif Z., Vanderhyden B. C., Kallikreins 5, 6 and 10 differentially alter pathophysiology and overall survival in an ovarian cancer xenograft model. PLoS ONE 2011 6 11 e26075 10.1371/journal.pone.0026075
83. Diamandis E. P., Yousef G. M., Luo L. Y., Magklara A., Obiezu C. V., The new human kallikrein gene family: implications in carcinogenesis. Trends in Endocrinology and Metabolism 2000 11 2 54 60 2-s2.0-0034159946 10.1016/S1043-2760(99)00225-8 (Pubitemid 30106476)
84. Shvartsman H. S., Lu K. H., Lee J., Lillie J., Deavers M. T., Clifford S., Wolf J. K., Mills G. B., Bast Jr. R. C., Gershenson D. M., Schmandt R., Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecologic Oncology 2003 90 1 44 50 10.1016/S0090-8258(03)00257-9 (Pubitemid 37338074)
85. Jag U. R., Gharbaran R., Tanaka T., Sarojini S., Tamir A., Schindewolf C., Patel H. A., Sood A. K., Hu W., Tamir A., Patwa R., Blake P., McCue P., Goy A., Pecora A., Suh K. S., Kallikrein family proteases KLK6 and KLK7 are early detection and diagnostic biomarkers for serous and papillary serous subtypes of ovarian cancer. Cancer Biomarkers. In press
86. Yu J. X., Chao L., Chao J., Prostasin is a novel human serine proteinase from seminal fluid. Purification, tissue distribution, and localization in prostate gland. The Journal of Biological Chemistry 1994 269 29 18843 18848 2-s2.0-0028282969
87. Yu J. X., Chao L., Ward D. C., Chao J., Structure and chromosomal localization of the human prostasin (PRSS8) gene. Genomics 1996 32 3 334 340 2-s2.0-0029918450 10.1006/geno.1996.0127 (Pubitemid 26094491)
88. Verghese G. M., Gutknecht M. F., Caughey G. H., Prostasin regulates epithelial monolayer function: cell-specific Gpld1-mediated secretion and functional role for GPI anchor. American Journal of Physiology 2006 291 6 C1258 C1270 2-s2.0-33845308239 10.1152/ajpcell.00637.2005 (Pubitemid 44878597)
89. Friis S., Godiksen S., Bornholdt J., Selzer-Plon J., Rasmussen H. B., Bugge T. H., Lin C. Y., Vogel L. K., Transport via the transcytotic pathway makes prostasin available as a substrate for matriptase. The Journal of Biological Chemistry 2011 286 7 5793 5802 2-s2.0-79953137474 10.1074/jbc.M110.186874
90. Fu Y. Y., Gao W. L., Chen M., Chai K. X., Wang Y. L., Chen L. M., Prostasin regulates human placental trophoblast cell proliferation via the epidermal growth factor receptor signaling pathway. Human Reproduction 2010 25 3 623 632 2-s2.0-76749094535 10.1093/humrep/dep457
91. Mok S. C., Chao J., Skates S., Wong K. K., Yiu G. K., Muto M. G., Berkowitz R. S., Cramer D. W., Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. Journal of the National Cancer Institute 2001 93 19 1458 1464 2-s2.0-0035802183 (Pubitemid 32982674)
92. Costa F. P., Batista E. L. Jr., Zelmanowicz A., Svedman C., Devenz G., Alves S., da Silva A. S. M., Garicochea B., Prostasin, a potential tumor marker in ovarian cancer-a pilot study. Clinics 2009 64 7 641 644 2-s2.0-69149098620 10.1590/S1807-59322009000700006
93. Sun G., Qin J., Qiu Y., Gao Y., Yu Y., Deng Q., Zhong M., Microarray analysis of gene expression in the ovarian cancer cell line HO-8910 with silencing of the ZNF217 gene. Molecular Medicine Reports 2009 2 5 851 855 2-s2.0-69249206710 10.3892/mmr-00000183
94. Chen M., Chen L. M., Lin C. Y., Chai K. X., The epidermal growth factor receptor (EGFR) is proteolytically modified by the Matriptase-Prostasin serine protease cascade in cultured epithelial cells. Biochimica et Biophysica Acta 2008 1783 5 896 903 2-s2.0-41949136687 10.1016/j.bbamcr.2007.10.019
95. Rahilly M., Carder P. J., Al Nafussi A., Harrison D. J., Distribution of glutathione S-transferase isoenzymes in human ovary. Journal of Reproduction and Fertility 1991 93 2 303 311 2-s2.0-0026315946
96. Coughlin S. S., Hall I. J., Glutathione S-transferase polymorphisms and risk of ovarian cancer: a HuGE review. Genetics in Medicine 2002 4 4 250 257 2-s2.0-0036651390 10.1097/00125817-200207000-00003 (Pubitemid 44698559)
97. Beeghly A., Katsaros D., Chen H., Fracchioli S., Zhang Y., Massobrio M., Risch H., Jones B., Yu H., Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecologic Oncology 2006 100 2 330 337 2-s2.0-30444435538 10.1016/j.ygyno.2005.08.035 (Pubitemid 43075265)
98. Economopoulos K. P., Sergentanis T. N., Vlahos N. F., Glutathione S-transferase M1, T1, and P1 polymorphisms and ovarian cancer risk: a meta-analysis. International Journal of Gynecological Cancer 2010 20 5 732 737 2-s2.0-77956816039 10.1111/IGC.0b013e3181dedeb5
99. Townsend D. M., Tew K. D., Tapiero H., The importance of glutathione in human disease. Biomedicine and Pharmacotherapy 2003 57 3 145 155 2-s2.0-0037733975 10.1016/S0753-3322(03)00043-X (Pubitemid 36740460)
100. Howells R. E. J., Redman C. W. E., Dhar K. K., Sarhanis P., Musgrove C., Jones P. W., Alldersea J., Fryer A. A., Hoban P. R., Strange R. C., Association of glutathione S-transferase GSTM1 and GSTT1 null genotypes with clinical outcome in epithelial ovarian cancer. Clinical Cancer Research 1998 4 10 2439 2445 2-s2.0-0031784414 (Pubitemid 28477910)
101. Howells R. E. J., Holland T., Dhar K. K., Redman C. W. E., Hand P., Hoban P. R., Jones P. W., Fryer A. A., Strange R. C., Glutathione S-transferase GSTM1 and GSTT1 genotypes in ovarian cancer: association with p53 expression and survival. International Journal of Gynecological Cancer 2001 11 2 107 112 2-s2.0-0035040418 10.1046/j.1525-1438.2001.011002107.x (Pubitemid 32381658)
102. McIlwain C. C., Townsend D. M., Tew K. D., Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 2006 25 11 1639 1648 2-s2.0-33645111448 10.1038/sj.onc.1209373
103. Tew K. D., Manevich Y., Grek C., Xiong Y., Uys J., Townsend D. M., The role of glutathione S-transferase P in signaling pathways and S-glutathionylation in cancer. Free Radical Biology and Medicine 2011 51 2 299 313 2-s2.0-79959362325 10.1016/j.freeradbiomed.2011.04.013
104. Dainty L. A., Risinger J. I., Morrison C., Chandramouli G. V. R., Bidus M. A., Zahn C., Rose G. S., Fowler J., Berchuck A., Maxwell G. L., Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma. Gynecologic Oncology 2007 105 3 563 570 2-s2.0-34248384824 10.1016/j.ygyno.2006.10.063 (Pubitemid 46734177)
105. Kelemen L. E., The role of folate receptor α in cancer development, progression and treatment: cause, consequence or innocent bystander? International Journal of Cancer 2006 119 2 243 250 2-s2.0-33745204461 10.1002/ijc.21712
106. Chen Y. L., Chang M. C., Huang C. Y., Chiang Y. C., Lin H. W., Chen C. A., Hsieh C. Y., Cheng W. F., Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response. Molecular Oncology 2012 6 3 360 369 10.1016/j.molonc.2011.11.010
107. van Dam G. M., Themelis G., Crane L. M. A., Harlaar N. J., Pleijhuis R. G., Kelder W., Sarantopoulos A., De Jong J. S., Arts H. J. G., Van Der Zee A. G. J., Bart J., Low P. S., Ntziachristos V., Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor- α targeting: first in-human results. Nature Medicine 2011 17 10 1315 1319 10.1038/nm.2472
108. Yuan Y., Nymoen D. A., Dong H. P., Bjørang O., Shih I. M., Low P. S., Trope' C. G., Davidson B., Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions. Human Pathology 2009 40 10 1453 1460 2-s2.0-69949132462 10.1016/j.humpath.2009.02.013
109. Wu M., Gunning W., Ratnam M., Expression of folate receptor type α in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiology Biomarkers and Prevention 1999 8 9 775 782 2-s2.0-0032883172 (Pubitemid 29445014)
110. Basal E., Eghbali-Fatourechi G. Z., Kalli K. R., Hartmann L. C., Goodman K. M., Goode E. L., Kamen B. A., Low P. S., Knutson K. L., Functional folate receptor alpha is elevated in the blood of ovarian cancer patients. PLoS ONE 2009 4 7 2-s2.0-67651108570 10.1371/journal.pone.0006292 e6292
111. Markert S., Lassmann S., Gabriel B., Klar M., Werner M., Gitsch G., Kratz F., Hasenburg A., Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue. Anticancer Research 2008 28 6A 3567 3572 2-s2.0-58149158183
112. Kalli K. R., Oberg A. L., Keeney G. L., Christianson T. J. H., Low P. S., Knutson K. L., Hartmann L. C., Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecologic Oncology 2008 108 619 626 2-s2.0-39249085399 10.1016/j.ygyno.2007.11.020
113. Crane L. M., Arts H. J., van Oosten M., Low P. S., van der Zee A. G., van Dam G. M., Bart J., The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer. Cellular Oncology 2012 35 1 9 18
114. Miotti S., Bagnoli M., Tomassetti A., Colnaghi M. I., Canevari S.,
115. van Jaarsveld M. T. M., Helleman J., Berns E. M. J. J., Wiemer E. A. C., MicroRNAs in ovarian cancer biology and therapy resistance. International Journal of Biochemistry and Cell Biology 2010 42 8 1282 1290 2-s2.0-77952671554 10.1016/j.biocel.2010.01.014
116. Iorio M. V., Visone R., Di Leva G., Donati V., Petrocca F., Casalini P., Taccioli C., Volinia S., Liu C. G., Alder H., Calin G. A., Ménard S., Croce C. M., MicroRNA signatures in human ovarian cancer. Cancer Research 2007 67 18 8699 8707 2-s2.0-34548746977 10.1158/0008-5472.CAN-07-1936 (Pubitemid 47437445)
117. Taylor D. D., Gercel-Taylor C., MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecologic Oncology 2008 110 1 13 21 2-s2.0-45449093192 10.1016/j.ygyno.2008.04.033 (Pubitemid 351853251)
118. Hu X., Macdonald D. M., Huettner P. C., Feng Z., El Naqa I. M., Schwarz J. K., Mutch D. G., Grigsby P. W., Powell S. N., Wang X., A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecologic Oncology 2009 114 3 457 464 2-s2.0-67651165020 10.1016/j.ygyno.2009.05.022
119. Yang H., Kong W., He L., Zhao J. J., O'Donnell J. D., Wang J., Wenham R. M., Coppola D., Kruk P. A., Nicosia S. V., Cheng J. Q., MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Research 2008 68 2 425 433 2-s2.0-39049086391 10.1158/0008-5472.CAN-07-2488 (Pubitemid 351380068)
120. Li Z., Hu S., Wang J., Cai J., Xiao L., Yu L., Wang Z., MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecologic Oncology 2010 119 1 125 130 2-s2.0-77956648184 10.1016/j.ygyno.2010.06.004
121. Chang B., Liu G., Xue F., Rosen D. G., Xiao L., Wang X., Liu J., ALDH1 expression correlates with favorable prognosis in ovarian cancers. Modern Pathology 2009 22 6 817 823 2-s2.0-67349255442 10.1038/modpathol.2009.35
122. Steffensen K. D., Alvero A. B., Yang Y., Waldstrøm M., Hui P., Holmberg J. C., Silasi D.-A., Jakobsen A., Rutherford T., Mor G., Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. Journal of Oncology 2011 2011 12 620523 10.1155/2011/620523
123. Silva I. A., Bai S., McLean K., Yang K., Griffith K., Thomas D., Ginestier C., Johnston C., Kueck A., Reynolds R. K., Wicha M. S., Buckanovich R. J., Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Research 2011 71 11 3991 4001 2-s2.0-79957917044 10.1158/0008-5472.CAN-10-3175
124. Landen C. N. Jr., Goodman B., Katre A. A., Steg A. D., Nick A. M., Stone R. L., Miller L. D., Mejia P. V., Jennings N. B., Gershenson D. M., Bast R. C., Coleman R. L., Lopez-Berestein G., Sood A. K., Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Molecular Cancer Therapeutics 2010 9 12 3186 3199 2-s2.0-78650455641 10.1158/1535-7163.MCT-10-0563
125. Penumatsa K., Edassery S. L., Barua A., Bradaric M. J., Luborsky J. L., Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors. Journal of Ovarian Research 2010 3 1, article 28 2-s2.0-78650375203 10.1186/1757-2215-3-28
126. Deng S., Yang X., Lassus H., Liang S., Kaur S., Ye Q., Li C., Wang L. P., Roby K. F., Orsulic S., Connolly D. C., Zhang Y., Montone K., Bützow R., Coukos G., Zhang L., Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS ONE 2010 5 4 2-s2.0-77956302698 10.1371/journal.pone.0010277 e10277
127. Kurebayashi J., Kanomata N., Moriya T., Kozuka Y., Watanabe M., Sonoo H., Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype. BMC Cancer 2010 10, article 568 2-s2.0-77957987525 10.1186/1471-2407-10-568
128. Chatterjee M., Tainsky M. A., Autoantibodies as biomarkers for ovarian cancer. Cancer Biomarkers 2010 8 4-5 187 201 10.3233/CBM-2011-0213
129. Li C., Sasaroli D., Chen X., Hu J., Sandaltzopoulos R., Omidi Y., Coukos G., Tumor vascular biomarkers: new opportunities for cancer diagnostics. Cancer Biomarkers 2010 8 4-5 253 271 10.3233/CBM-2011-0217
130. Buckanovich R. J., Sasaroli D., O'Brien-Jenkins A., Botbyl J., Hammond R., Katsaros D., Sandaltzopoulos R., Liotta L. A., Gimotty P. A., Coukos G., Tumor vascular proteins as biomarkers in ovarian cancer. Journal of Clinical Oncology 2007 25 7 852 861 2-s2.0-33947545030 10.1200/JCO.2006.08.8583 (Pubitemid 350002886)
131. Abbott K. L., Glycomic analysis of ovarian cancer: past, present, and future. Cancer Biomarkers 2010 8 4-5 273 280 10.3233/CBM-2011-0218
132. An H. J., Lebrilla C. B., A glycomics approach to the discovery of potential cancer biomarkers. Methods in Molecular Biology 2010 600 199 213 2-s2.0-74049087478
133. Roberson C. D., Atay S., Gercel-Taylor C., Taylor D. D., Tumor-derived exosomes as mediators of disease and potential diagnostic biomarkers. Cancer Biomarkers 2010 8 4-5 281 287 10.3233/CBM-2011-0211
134. Nowosinska E., Avril S., Murray I., Szyszko T., Avril N., FDG-PET/CT as a molecular biomarker in ovarian cancer. Cancer Biomarkers 2010 8 4-5 167 175 10.3233/CBM-2011-0219
135. Lin Y. H., Yang-Yen H. F., The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. The Journal of Biological Chemistry 2001 276 49 46024 46030 2-s2.0-0035824560 10.1074/jbc.M105132200
136. Simon I., Katsaros D., Rigault de la Longrais I., Massobrio M., Scorilas A., Kim N. W., Sarno M. J., Wolfert R. L., Diamandis E. P., B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. Gynecologic Oncology 2007 106 2 334 341 2-s2.0-34547132812 10.1016/j.ygyno.2007.03.035 (Pubitemid 47096655)
137. Simon I., Zhuo S., Corral L., Diamandis E. P., Sarno M. J., Wolfert R. L., Kim N. W., B7-H4 Is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Research 2006 66 3 1570 1575 2-s2.0-32944472874 10.1158/0008-5472.CAN-04-3550 (Pubitemid 43259939)
138. Kim J. H., Skates S. J., Uede T., Wong K. K., Schorge J. O., Feltmate C. M., Berkowitz R. S., Cramer D. W., Mok S. C., Osteopontin as a potential diagnostic biomarker for ovarian cancer. The Journal of the American Medical Association 2002 287 13 1671 1679 2-s2.0-0037012469 (Pubitemid 34289219)
139. Dupont J., Tanwar M. K., Thaler H. T., Fleisher M., Kauff N., Hensley M. L., Sabbatini P., Anderson S., Aghajanian C., Holland E. C., Spriggs D. R., Early detection and prognosis of ovarian cancer using serum YKL-40. Journal of Clinical Oncology 2004 22 16 3330 3339 2-s2.0-4344704083 10.1200/JCO.2004.09.112 (Pubitemid 41103690)
140. Häusler S. F. M., Keller A., Chandran P. A., Ziegler K., Zipp K., Heuer S., Krockenberger M., Engel J. B., Hönig A., Scheffler M., Dietl J., Wischhusen J., Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. British Journal of Cancer 2010 103 5 693 700 2-s2.0-77955981654 10.1038/sj.bjc.6605833
141. Shah C. A., Lowe K. A., Paley P., Wallace E., Anderson G. L., McIntosh M. W., Andersen M. R., Scholler N., Bergan L. A., Thorpe J. D., Urban N., Drescher C. W., Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiology Biomarkers and Prevention 2009 18 5 1365 1372 2-s2.0-66549097456 10.1158/1055-9965.EPI-08- 1034
142. Lakhani S. R., Manek S., Penault-Llorca F., Flanagan A., Arnout L., Merrett S., McGuffog L., Steele D., Devilee P., Klijn J. G. M., Meijers-Heijboer H., Radice P., Pilotti S., Nevanlinna H., Butzow R., Sobol H., Jacquemier J., Lyonet D. S., Neuhausen S. L., Weber B., Wagner T., Winqvist R., Bignon Y. J., Monti F., Schmitt F., Lenoir G., Seitz S., Hamman U., Pharoah P., Lane G., Ponder B., Bishop D. T., Easton D. F., Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clinical Cancer Research 2004 10 7 2473 2481 2-s2.0-11144354423 10.1158/1078-0432.CCR-1029-3 (Pubitemid 38445709)
143. Loveday C., Turnbull C., Ramsay E., Hughes D., Ruark E., Frankum J. R., Bowden G., Kalmyrzaev B., Warren-Perry M., Snape K., Adlard J. W., Barwell J., Berg J., Brady A. F., Brewer C., Brice G., Chapman C., Cook J., Davidson R., Donaldson A., Douglas F., Greenhalgh L., Henderson A., Izatt L., Kumar A., Lalloo F., Miedzybrodzka Z., Morrison P. J., Paterson J., Porteous M., Rogers M. T., Shanley S., Walker L., Eccles D., Evans D. G., Renwick A., Seal S., Lord C. J., Ashworth A., Reis-Filho J. S., Antoniou A. C., Rahman N., Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nature Genetics 2011 43 9 879 882 10.1038/ng.893
144. Bell D., Berchuck A., Birrer M., Chien J., Cramer D. W., Dao F., Dhir R., Disaia P., Gabra H., Glenn P., Godwin A. K., Gross J., Hartmann L., Huang M., Huntsman D. G., Iacocca M., Imielinski M., Kalloger S., Karlan B. Y., Levine D. A., Mills G. B., Morrison C., Mutch D., Olvera N., Orsulic S., Park K., Petrelli N., Rabeno B., Rader J. S., Sikic B. I., Smith-Mccune K., Sood A. K., Bowtell D., Penny R., Testa J. R., Chang K., Dinh H. H., Drummond J. A., Fowler G., Gunaratne P., Hawes A. C., Kovar C. L., Lewis L. R., Morgan M. B., Newsham I. F., Santibanez J., Reid J. G., Trevino L. R., Wu Y.-Q., Wang M., Muzny D. M., Wheeler D. A., Gibbs R. A., Getz G., Lawrence M. S., Cibulskis K., Sivachenko A. Y., Sougnez C., Voet D., Wilkinson J., Bloom T., Ardlie K., Fennell T., Baldwin J., Gabriel S., Lander E. S., Ding L., Fulton R. S., Koboldt D. C., McLellan M. D., Wylie T., Walker J., O'Laughlin M., Dooling D. J., Fulton L., Abbott R., Dees N. D., Zhang Q., Kandoth C., Wendl M., Schierding W., Shen D., Harris C. C., Schmidt H., Kalicki J., Delehaunty K. D., Fronick C. C., Demeter R., Cook L., Wallis J. W., Lin L., Magrini V. J., Hodges J. S., Eldred J. M., Smith S. M., Pohl C. S., Vandin F., Raphael B. J., Weinstock G. M., Mardis E. R., Wilson R. K., Meyerson M., Winckler W., Getz G., Verhaak R. G. W., Carter S. L., Mermel C. H., Saksena G., Nguyen H., Onofrio R. C., Lawrence M. S., Hubbard D., Gupta S., Crenshaw A., Ramos A. H., Ardlie K., Chin L., Protopopov A., Zhang J., Kim T. M., Perna I., Xiao Y., Zhang H., Ren G., Sathiamoorthy N., Park R. W., Lee E., Park P. J., Kucherlapati R., Absher D. M., Waite L., Sherlock G., Brooks J. D., Li J. Z., Xu J., Myers R. M., Laird P. W., Cope L., Herman J. G., Shen H., Weisenberger D. J., Noushmehr H., Pan F., Triche Jr T., Berman B. P., Van Den Berg D. J., Buckley J., Baylin S. B., Spellman P. T., Purdom E., Neuvial P., Bengtsson H., Jakkula L. R., Durinck S., Han J., Dorton S., Marr H., Choi Y. G., Wang V., Wang N. J., Ngai J., Conboy J. G., Parvin B., Feiler H. S., Speed T. P., Gray J. W., Levine D. A., Socci N. D., Liang Y., Taylor B. S., Schultz N., Borsu L., Lash A. E., Brennan C., Viale A., Sander C., Ladanyi M., Hoadley K. A., Meng S., Du Y., Shi Y., Li L., Turman Y. J., Zang D., Helms E. B., Balu S., Zhou X., Wu J., Topal M. D., Hayes D. N., Perou C. M., Getz G., Voet D., Saksena G., Zhang J., Zhang H., Wu C. J., Shukla S., Cibulskis K., Lawrence M. S., Sivachenko A., Jing R., Park R. W., Liu Y., Park P. J., Noble M., Chin L., Carter H., Kim D., Karchin R., Spellman P. T., Purdom E., Neuvial P., Bengtsson H., Durinck S., Han J., Korkola J. E., Heiser L. M., Cho R. J., Hu Z., Parvin B., Speed T. P., Gray J. W., Schultz N., Cerami E., Taylor B. S., Olshen A., Reva B., Antipin Y., Shen R., Mankoo P., Sheridan R., Ciriello G., Chang W. K., Bernanke J. A., Borsu L., Levine D. A., Ladanyi M., Sander C., Haussler D., Benz C. C., Stuart J. M., Benz S. C., Sanborn J. Z., Vaske C. J., Zhu J., Szeto C., Scott G. K., Yau C., Hoadley K. A., Du Y., Balu S., Hayes D. N., Perou C. M., Wilkerson M. D., Zhang N., Akbani R., Baggerly K. A., Yung W. K., Mills G. B., Weinstein J. N., Penny R., Shelton T., Grimm D., Hatfield M., Morris S., Yena P., Rhodes P., Sherman M., Paulauskis J., Millis S., Kahn A., Greene J. M., Sfeir R., Jensen M. A., Chen J., Whitmore J., Alonso S., Jordan J., Chu A., Zhang J., Barker A., Compton C., Eley G., Ferguson M., Fielding P., Gerhard D. S., Myles R., Schaefer C., Mills Shaw K. R., Vaught J., Vockley J. B., Good P. J., Guyer M. S., Ozenberger B., Peterson J., Thomson E., Integrated genomic analyses of ovarian carcinoma. Nature 2011 474 7353 609 615 10.1038/nature10166
145. Singer G., Oldt R., Cohen Y., Wang B. G., Sidransky D., Kurman R. J., Shih I. M., Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. Journal of the National Cancer Institute 2003 95 6 484 486 2-s2.0-0037454224 (Pubitemid 36432423)
146. Palacios J., Gamallo C., Mutations in the β -catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Research 1998 58 7 1344 1347 2-s2.0-0032054206 (Pubitemid 28193586)
147. Kuo K. T., Mao T. L., Jones S., Veras E., Ayhan A., Wang T. L., Glas R., Slamon D., Velculescu V. E., Kuman R. J., Shih I. M., Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. American Journal of Pathology 2009 174 5 1597 1601 2-s2.0-65649128979 10.2353/ajpath.2009.081000
148. Wiegand K. C., Shah S. P., Al-Agha O. M., Zhao Y., Tse K., Zeng T., Senz J., McConechy M. K., Anglesio M. S., Kalloger S. E., Yang W., Heravi-Moussavi A., Giuliany R., Chow C., Fee J., Zayed A., Prentice L., Melnyk N., Turashvili G., Delaney A. D., Madore J., Yip S., McPherson A. W., Ha G., Bell L., Fereday S., Tam A., Galletta L., Tonin P. N., Provencher D., Miller D., Jones S. J. M., Moore R. A., Morin G. B., Oloumi A., Boyd N., Aparicio S. A., Shih I.-M., Mes-Masson A.-M., Bowtell D. D., Hirst M., Gilks B., Marra M. A., Huntsman D. G., ARID1A mutations in endometriosis-associated ovarian carcinomas. The New England Journal of Medicine 2010 363 16 1532 1543 10.1056/NEJMoa1008433
149. Heravi-Moussavi A., Anglesio M. S., Cheng S.-W. G., Senz J., Yang W., Prentice L., Fejes A. P., Chow C., Tone A., Kalloger S. E., Hamel N., Roth A., Ha G., Wan A. N. C., Maines-Bandiera S., Salamanca C., Pasini B., Clarke B. A., Lee A., Lee C.-H., Zhao C., Young R. H., Aparicio S. A., Sorensen P. H. B., Woo M. M. M., Boyd N., Jones S. J. M., Hirst M., Marra M. A., Gilks B., Shah S. P., Foulkes W. D., Morin G. B., Huntsman D. G., Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. The New England Journal of Medicine 2012 366 3 234 242 10.1056/NEJMoa1102903
150. Nolen B. M., Lokshin A. E., Screening for ovarian cancer: old tools, new lessons. Cancer Biomarkers 2010 8 4-5 177 186 10.3233/CBM-2011-0210